{"id":11936,"date":"2023-11-07T00:31:00","date_gmt":"2023-11-06T16:31:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11936"},"modified":"2024-11-10T00:34:35","modified_gmt":"2024-11-09T16:34:35","slug":"teva-partners-with-cr-guangdong-to-launch-fremanezumab-for-migraines-in-chinas-gba","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11936","title":{"rendered":"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA"},"content":{"rendered":"\n

Israel-based generics specialist Teva (NYSE: TEVA<\/a>) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong’s logistics and supply chain management expertise to support the introduction of Teva’s migraine therapy, fremanezumab, in the Greater Bay Area (GBA) of China.<\/p>\n\n\n\n

Fremanezumab’s Market Introduction and Approval<\/strong>
Teva\u2019s fremanezumab, a clinically needed drug for the treatment of migraines, received approval in China in July 2023, specifically targeting the GBA region. CR Guangdong, which has been approved by Guangdong\u2019s medical products administration to import and deliver the therapy, is poised to play a crucial role in the drug’s distribution. Fremanezumab was first administered at Guangzhou United Family Hospital in early July, marking a significant step in improving access to this therapy for migraine sufferers in the area.<\/p>\n\n\n\n

Supply Chain and Logistics Support<\/strong>
CR Guangdong’s capabilities in logistics delivery and supply chain management are expected to enhance the efficiency and reach of Teva’s fremanezumab in the GBA. This strategic partnership underscores the importance of robust distribution networks in ensuring that innovative therapies like fremanezumab are made available to patients who need them, thereby improving treatment outcomes and quality of life for those affected by migraines.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1975,26,1072,1071],"class_list":["post-11936","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-resources-pharmaceutical","tag-greater-bay-area","tag-nyse-teva","tag-teva-pharmaceutical"],"yoast_head":"\nTeva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China's GBA - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong's logistics and supply chain management expertise to support the introduction of Teva's migraine therapy, fremanezumab, in the Greater Bay Area (GBA) of China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11936\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China's GBA\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11936\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-06T16:31:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-09T16:34:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11936#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11936\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA\",\"datePublished\":\"2023-11-06T16:31:00+00:00\",\"dateModified\":\"2024-11-09T16:34:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11936\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Resources Pharmaceutical\",\"Greater Bay Area\",\"NYSE: TEVA\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11936#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11936\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11936\",\"name\":\"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China's GBA - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-06T16:31:00+00:00\",\"dateModified\":\"2024-11-09T16:34:35+00:00\",\"description\":\"Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong's logistics and supply chain management expertise to support the introduction of Teva's migraine therapy, fremanezumab, in the Greater Bay Area (GBA) of China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11936#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11936\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11936#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China's GBA - Insight, China's Pharmaceutical Industry","description":"Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong's logistics and supply chain management expertise to support the introduction of Teva's migraine therapy, fremanezumab, in the Greater Bay Area (GBA) of China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11936","og_locale":"en_US","og_type":"article","og_title":"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China's GBA","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11936","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-06T16:31:00+00:00","article_modified_time":"2024-11-09T16:34:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11936#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11936"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA","datePublished":"2023-11-06T16:31:00+00:00","dateModified":"2024-11-09T16:34:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11936"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Resources Pharmaceutical","Greater Bay Area","NYSE: TEVA","Teva Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11936#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11936","url":"https:\/\/flcube.com\/?p=11936","name":"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China's GBA - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-06T16:31:00+00:00","dateModified":"2024-11-09T16:34:35+00:00","description":"Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong's logistics and supply chain management expertise to support the introduction of Teva's migraine therapy, fremanezumab, in the Greater Bay Area (GBA) of China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11936#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11936"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11936#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11936"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11936\/revisions"}],"predecessor-version":[{"id":11937,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11936\/revisions\/11937"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}